ImmunitasBio provides biotechnology research services focused on immunology, offering custom assay development and bioanalytical methods for vaccine and immuno-oncology research. The company enables faster and more efficient evaluation of immunological functions, addressing the need for precise and scalable solutions in healthcare innovation.
Funding
Funding not disclosed
Founders
Product
Problem
The development of vaccines and immunotherapies requires precise and scalable methods to evaluate immunological functions. Existing bioanalytical methods often lack the necessary sensitivity and customization for novel drugs and biomarkers.
Solution
ImmunitasBio offers custom assay development and bioanalytical services specializing in immunology, vaccine research, and immuno-oncology. The company designs and develops cell-based assays to assess the immunological functions of vaccines, including inactivated, live-attenuated, viral-vector, and mRNA-based vaccines. ImmunitasBio also provides a platform for immuno-oncological therapies, offering specific and sensitive bioanalytical methods and customized oncological assays. Additionally, they develop novel immunoassays for drugs and biomarkers, identifying optimal reagents and consumables and managing subcontracting and testing throughout the development process.
Target Audience
The primary customers are researchers and companies in the fields of immunology, vaccine development, immuno-oncology, and drug development.
Features
- Custom design and development of cell-based assays for vaccine analysis
- Development of specific bioanalytical methods for immuno-oncology therapies
- Proprietary T cell immunity test kit for COVID-19
- ELISA kits for quantifying soluble proteins in serum, plasma, and cell culture supernatants
- Luminex multiplex assays for simultaneous quantification of multiple analytes
- Flow cytometry services for cell characterization and analysis
- ELISpot assays for detecting cytokine-secreting cells
- Virucidal, bactericidal, and sporicidal testing services